China Meheco(SH:600056) Di Yi Cai Jing·2025-12-27 06:17Core Viewpoint - The investigation of Gao Yuwen, former chairman of China National Pharmaceutical Group Co., Ltd. (China Pharmaceutical), highlights ongoing anti-corruption efforts within the company, which has seen multiple executives investigated for serious violations in recent years [1][2]. Group 1: Investigation and Leadership Changes - Gao Yuwen is under disciplinary review and investigation by the Central Commission for Discipline Inspection and the Tianjin Municipal Supervisory Committee for serious violations [1]. - Since 2024, at least 11 executives or former executives from China Pharmaceutical and its subsidiaries have been investigated for serious violations [2]. - Li Xin, former assistant general manager, was also investigated for serious violations and had overlapping work periods with Gao Yuwen [2]. Group 2: Company Structure and Market Position - China Pharmaceutical, established in 1983, is the only pharmaceutical and medical device production and operation platform under the General Technology Group [1]. - As of December 27, 2025, the market capitalization of China Pharmaceutical on the A-share market is 15.662 billion yuan [1]. Group 3: Financial Performance - In 2024, the company reported operating revenue of 34.148 billion yuan, a year-on-year decrease of 12.04%, and a net profit attributable to shareholders of 0.535 billion yuan, down 48.91% [3]. - In the first half of 2025, the company achieved operating revenue of 17.076 billion yuan, a decline of 6.71%, with a net profit of 0.294 billion yuan, down 16.19% [3]. - For the first three quarters of 2025, the net profit attributable to shareholders was 0.477 billion yuan, reflecting a year-on-year decrease of 4.64% [3].